To elucidate the mechanisms of progressive T-cell exhaustion underlying acquired resistance to ICIs, we initially developed an in vivo model by subcutaneously implanting Hepa1-6 HCC cells into mice and subsequently treating them with either an anti-PD1 antibody or an isotype control (Fig. 1A). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.